We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer (LUTRAERL)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00473083
First Posted: May 14, 2007
Last Update Posted: April 4, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hoffmann-La Roche
Information provided by (Responsible Party):
British Columbia Cancer Agency
  Purpose

The purpose of this trial is to determine if rash caused by erlotinib can be successfully treated and if so to determine the optimal treatment approach.

Hypothesis:

Hypothesis 1: If the incidence of rash is 50% while on erlotinib, prophylactic monotherapy with minocycline can prevent occurrence in 50% of these patients.

Hypothesis 2: Treatment of rash is successful in improving rash by at least one Grade in 80% of patients.

Hypothesis 3: In patients with untreated rash, the rash will be self-limiting in 25% of patients, and 65% will be grade 1, 2A, and 2b. Ten percent will be grade 3 requiring treatment with monotherapy intervention.


Condition Intervention Phase
Rash Drug: Minocycline Drug: Clindamycin 2% in hydrocortisone 1% lotion Drug: Erlotinib Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomized Controlled Trial of Systemic and Topical Treatments for Rash Secondary to Erlotinib in Advanced Stage IIIB or IV Non-Small Cell Lung Cancer

Resource links provided by NLM:


Further study details as provided by British Columbia Cancer Agency:

Primary Outcome Measures:
  • Overall Incidence of Rash [ Time Frame: From onset of rash until resolution, up to 4 weeks following progression, an average of 1 year ]

    The overall incidence of any grade of erlotinib-induced rash among the three treatment arms.

    For overall incidence of rash a binary variable will be designed. Data will be summarized with percentages by treatment group.


  • Time Duration From Onset of Rash Until Resolution [ Time Frame: From onset of rash until resolution, up to 4 weeks following progression, an average of 1 year ]

    To investigate if the rash caused by erlotinib is self-limiting.

    A time variable will be defined to identify the duration from onset of rash until resolution. Resolution will be defined as resolution to severity Grade 1 for patients with rash of maximum severity grade >1 and resolution to Grade 0 for patients with maximum rash severity = 1. For patients where resolution is not observed the time considered will be the maximum time from onset of rash until end of the study.

    The analyses will be performed using the following two sub-populations: subjects with maximum severity of rash of Grade 1, 2a and 2b will constitute one sub-population and Grade 3 will be considered the second sub-population.

    The comparisons will be performed primarily for Group 1 vs. Group 3 and Group 2 vs. Group 3 and secondly for Group 1 vs. Group 2.


  • Overall Incidence of Grade 3 Rash [ Time Frame: From onset of rash until resolution, up to 4 weeks following progression, on average of 1 year ]

    The overall incidence of grade 3 erlotinib-induced rash among the three treatment arms.

    For overall incidence of rash a binary variable will be designed. Data will be summarized with percentages by treatment group.



Secondary Outcome Measures:
  • Severity of Rash Caused by Erlotinib [ Time Frame: Onset until resolution, up to 4 weeks following progression, on average of 1 year ]
    The maximum severity of rash per subject will be summarized by treatment group. The summary will include only subjects who indicated any occurrence of rash.

  • Overall Survival [ Time Frame: Until death ]
  • Duration of Treatment [ Time Frame: Up to one year ]
  • Time to First Presentation of Rash [ Time Frame: Up to onset of rash while on study treatment ]

Enrollment: 150
Study Start Date: January 2009
Study Completion Date: August 2013
Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm 1: Prophylactic Treatment
Participants will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Drug: Minocycline
Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Other Names:
  • Dynacin
  • Minocin
  • Minocin PAC
  • Solodyn
  • Vectrin
  • Myrac
Drug: Clindamycin 2% in hydrocortisone 1% lotion

Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.

If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Drug: Erlotinib
Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
Other Name: Tarceva
Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
Experimental: Arm 2: Reactive Treatment

Pts will receive treatment at initiation of rash. Tx is dependent on grading of rash as follows:

Grade 1 or 2A: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied twice daily until resolution of rash by one grade

Grade 2B: Topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash by 1 grade. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.

Grade 3: Pts will discontinue tx with erlotinib 150mg for 1 week and restart at 100mg once daily.

Tx with topical clindamycin 2%, with hydrocortisone 1% in lotion base applied 2x daily and oral minocycline 100mg 2x daily for a min. of 4 weeks and continuing thereafter, as required, until resolution of rash to Grade 1 or 2A. Scalp lesions will be treated with a topical clindamycin 2%, triamcinolone acetonide 0.1% soln.

Drug: Minocycline
Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Other Names:
  • Dynacin
  • Minocin
  • Minocin PAC
  • Solodyn
  • Vectrin
  • Myrac
Drug: Clindamycin 2% in hydrocortisone 1% lotion

Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.

If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Drug: Erlotinib
Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
Other Name: Tarceva
Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
Experimental: Arm 3: No Treatment Unless Severe (Grade 3)
This is the control group. Patients will be treated only if grade 3 rash develops. For grade 3 rash, treatment will be in accordance with that of Grade 3 rash in Treatment Arm 2.
Drug: Minocycline
Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
Other Names:
  • Dynacin
  • Minocin
  • Minocin PAC
  • Solodyn
  • Vectrin
  • Myrac
Drug: Clindamycin 2% in hydrocortisone 1% lotion

Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.

If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles.

Drug: Erlotinib
Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
Other Name: Tarceva
Drug: Topical clindamycin 2%, triamcinolone acetonide 0.1% soln
Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water

Detailed Description:

Erlotinib has been shown to prolong survival in NSCLC patients who are no longer candidates for further chemotherapy. In July 2005, erlotinib was approved in Canada for the treatment of patients with locally advanced or metastatic NSCLC, following failure of first or second-line chemotherapy.

Erlotinib's side effect profile includes rash. The incidence of rash in clinical trials has been reported to be approximately 50 - 75%, and has been hypothesised to parallel tumour response (20).

The treatment of rash is controversial and many oncologists believe it is untreatable and self-limiting. The cause of the rash is not well understood but is felt to be a systemic event. Clinical experience of the investigators has suggested that minocycline 100 mg orally given twice-daily for 4 weeks and clindamycin 2% and hydrocortisone 1% topical cream for moderate to severe rash is a successful treatment.

The objectives of this trial are to better delineate the rash and its features and to describe an optimal treatment. Since the rash is often facial in distribution and can therefore lead to physical and psychological distress to the patient, a dermatology life quality index will also be completed throughout the study.

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytological documented diagnosis of inoperable, locally advanced, recurrent or metastatic (stage IIIB or stage IV) non-small cell lung cancer.
  2. Evidence of disease (measurable disease is not mandatory).
  3. 18 years of age or older.
  4. ECOG performance status of 0 - 3.
  5. Written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.

Exclusion Criteria:

  1. A history of another cancer other than basal cell carcinoma or cervical cancer in situ within the past 3 years
  2. Prior therapy with any type of cancer growth factor inhibitor (EGFR inhibitor or agent targeting this family of growth factor receptors)
  3. Life expectancy of less than 12 weeks.
  4. Ongoing toxic effects from prior chemotherapy.
  5. Pregnant or lactating women.
  6. Females of childbearing potential who have a positive or no pregnancy test (pregnancy tests must be obtained within 72 hours before starting therapy). (Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential).
  7. Male or female patients with reproductive potential who are unwilling to use effective and reliable contraceptive methods throughout the course of the study and for 90 days after the last dose of study medication.
  8. Ongoing treatment with any inhibitors or inducers of CYP3A4 activity
  9. Any unstable systemic disease (including active infection, grade 4 hypertension, unstable angina, congestive heart failure, hepatic, renal or metabolic disease).
  10. Any significant ophthalmologic abnormality, especially severe dry eye syndrome, keratoconjunctivitis sicca, Sjögren syndrome, severe exposure keratitis or any other disorder likely to increase the risk of corneal epithelial lesions.
  11. Unwilling or unable to comply with the protocol for the duration of the study.
  12. Patients who have experienced prior hypersensitivity reaction to active ingredients or excipients of the following compounds: erlotinib, minocycline, tetracycline, doxycycline or clindamycin.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00473083


Locations
Canada, Alberta
Tom Baker Cancer Centre
Calgary, Alberta, Canada, T2N 4N2
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2
Canada, British Columbia
BC Cancer Agency - Abbotsford
Abbotsford, British Columbia, Canada, V2S 0C2
Burnaby Hospital Regional Cancer Centre
Burnaby, British Columbia, Canada, V5G 2X6
BC Cancer Agency - Fraser Valley Centre
Vancouver, British Columbia, Canada, V3V 1Z2
BC Cancer Agency Vancouver Centre
Vancouver, British Columbia, Canada, V5Z 4E6
BC Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, Canada, V8R 6V5
Canada, Ontario
Mount Sinai Hospital
Toronto, Ontario, Canada, M5G 1X5
Princess Margaret Hospital
Toronto, Ontario, Canada, M5G 1Z6
Sponsors and Collaborators
British Columbia Cancer Agency
Hoffmann-La Roche
Investigators
Principal Investigator: Barb Melosky, MD British Columbia Cancer Agency
  More Information

Publications:
IMPATH Inc. Analysis of EGFr Expression in a selection of tumour types. IMPATH Study Number PFZ04. 1998-1999:1-16.
Ohsaki Y, Toyoshima E, Fujiuchi S, Nishigaki Y, Kikuchi K. EGR receptor (EGFR) expression correlates poor prognosis in non-small cell lung cancer (NSCLC) patients interacting with p53 overexpression (abstract). Proc Am Assoc Cancer Res 1997; 38:327.

Responsible Party: British Columbia Cancer Agency
ClinicalTrials.gov Identifier: NCT00473083     History of Changes
Other Study ID Numbers: ML21016
First Submitted: May 10, 2007
First Posted: May 14, 2007
Results First Submitted: January 22, 2016
Results First Posted: April 4, 2017
Last Update Posted: April 4, 2017
Last Verified: February 2017

Keywords provided by British Columbia Cancer Agency:
Rash
Erlotinib
Lung Cancer

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Erlotinib Hydrochloride
Triamcinolone diacetate
Clindamycin
Clindamycin palmitate
Triamcinolone hexacetonide
Hydrocortisone 17-butyrate 21-propionate
Hydrocortisone acetate
Cortisol succinate
Triamcinolone
Triamcinolone Acetonide
Hydrocortisone
Minocycline
Clindamycin phosphate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents